Login Register Cart 0
Meta-Analysis

PD-L1表达与胃癌临床病理特征的关系:一项综合meta分析

卷 31, 期 21, 2024

发表于: 27 October, 2023

页: [3198 - 3216] 页: 19

弟呕挨: 10.2174/0109298673263784230922060257

价格: $65

摘要

目的：程序性死亡配体-1(PD-L1)在胃癌患者中的表达水平是决定免疫药物使用的关键。PD-L1表达水平与临床特征的关系值得探讨。 方法：通过设置与PD-L1和胃癌相关的检索词，在四大数据库中进行了近乎全面的检索，检索截止日期为2022年9月1日。在删除重复后，对检索到的文献进行严格的纳入和排除标准筛选。接下来，采用纽卡斯尔-渥太华量表(NOS)评估纳入研究的质量。最后采用STATA15.1软件对数据进行处理并绘制图，采用比值比(odds ratio, or)评价合并效应大小。 结果：通过严格筛选，本研究共纳入85篇文献，并对文献质量进行评价后提取详细资料。在整个人群、亚非人群、欧美人群、以及CPS≥1的亚洲人群中进行分析的过程中，均发现PD-L1在胃癌中的表达与年龄、肿瘤大小、EBV感染、Her-2表达和微卫星状态相关。然而，该地区的亚组也发现了亚洲和西方地区的一些差异，这很有趣，值得进一步研究。本研究纳入的研究没有显著的发表偏倚。 结论：经过仔细分析，本研究发现年龄(>60岁)、肿瘤大小(>5cm)、EBV感染(+)、Her-2表达(+)、微卫星状态(MSI)、错配修复状态(dMMR)是胃癌中PD-L1阳性表达的危险因素。

关键词: PD-L1，程序性死亡配体-1,B7-H1，胃癌，临床病理特征，癌症。

« Previous Next »
[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Chen, Y.; Chen, T.; Fang, J.Y. Burden of gastrointestinal cancers in China from 1990 to 2019 and projection through 2029. Cancer Lett., 2023, 560, 216127.
[http://dx.doi.org/10.1016/j.canlet.2023.216127] [PMID: 36933779]
[3]
Zheng, R.S.; Zhang, S.W.; Sun, K.X.; Chen, R.; Wang, S.M.; Li, L.; Zeng, H.M.; Wei, W.W.; He, J. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi, 2023, 45(3), 212-220.
[PMID: 36944542]
[4]
Fang, X.; Xu, J.; Jin, K.; Qian, J. Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations. Int. Immunopharmacol., 2023, 118, 110062.
[http://dx.doi.org/10.1016/j.intimp.2023.110062] [PMID: 36965367]
[5]
Yoon, J.; Kim, T.Y.; Oh, D.Y. Recent progress in immunotherapy for gastric cancer. J. Gastric Cancer, 2023, 23(1), 207-223.
[http://dx.doi.org/10.5230/jgc.2023.23.e10] [PMID: 36751000]
[6]
Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A.C.; Liu, T.; Schenker, M.; Yanez, P.; Tehfe, M.; Kowalyszyn, R.; Karamouzis, M.V.; Bruges, R.; Zander, T.; Pazo-Cid, R.; Hitre, E.; Feeney, K.; Cleary, J.M.; Poulart, V.; Cullen, D.; Lei, M.; Xiao, H.; Kondo, K.; Li, M.; Ajani, J.A. A plain language summary of the CheckMate 649 study: Nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus. Future Oncol., 2023, 19(11), 739-752.
[http://dx.doi.org/10.2217/fon-2022-1149] [PMID: 36919706]
[7]
Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; Liu, T.; Schenker, M.; Yanez, P.; Tehfe, M.; Kowalyszyn, R.; Karamouzis, M.V.; Bruges, R.; Zander, T.; Pazo-Cid, R.; Hitre, E.; Feeney, K.; Cleary, J.M.; Poulart, V.; Cullen, D.; Lei, M.; Xiao, H.; Kondo, K.; Li, M.; Ajani, J.A. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet, 2021, 398(10294), 27-40.
[http://dx.doi.org/10.1016/S0140-6736(21)00797-2] [PMID: 34102137]
[8]
Entezam, M.; Sanaei, M.J.; Mirzaei, Y.; Mer, A.H.; Abdollahpour-Alitappeh, M.; Azadegan-Dehkordi, F.; Bagheri, N. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Life Sci., 2023, 318, 121459.
[http://dx.doi.org/10.1016/j.lfs.2023.121459] [PMID: 36720453]
[9]
Wang, J.; Yuan, R.; Song, W.; Sun, J.; Liu, D.; Li, Z. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: The historical perspective. J. Hematol. Oncol., 2017, 10(1), 34.
[http://dx.doi.org/10.1186/s13045-017-0403-5] [PMID: 28122590]
[10]
Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci., 2002, 99(19), 12293-12297.
[http://dx.doi.org/10.1073/pnas.192461099] [PMID: 12218188]
[11]
Xie, T.; Zhang, Z.; Zhang, X.; Qi, C.; Shen, L.; Peng, Z. Appropriate PD-L1 cutoff value for gastric cancer immunotherapy: A Systematic review and meta-analysis. Front. Oncol., 2021, 11, 646355.
[http://dx.doi.org/10.3389/fonc.2021.646355] [PMID: 34540656]
[12]
Gu, L.; Chen, M.; Guo, D.; Zhu, H.; Zhang, W.; Pan, J.; Zhong, X.; Li, X.; Qian, H.; Wang, X. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One, 2017, 12(8), e0182692.
[http://dx.doi.org/10.1371/journal.pone.0182692] [PMID: 28796808]
[13]
Kim, J.W.; Nam, K.H.; Ahn, S.H.; Park, D.J.; Kim, H.H.; Kim, S.H.; Chang, H.; Lee, J.O.; Kim, Y.J.; Lee, H.S.; Kim, J.H.; Bang, S.M.; Lee, J.S.; Lee, K.W. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer, 2016, 19(1), 42-52.
[http://dx.doi.org/10.1007/s10120-014-0440-5] [PMID: 25424150]
[14]
Rha, S.Y.; Ku, G.Y.; Kim, H.S.; Chung, H.C.; Amlashi, F.G.; Maru, D.M.; Fein, C.A.; Tang, L.H.; Zhou, W.; Wu, T.; Peter, S.A.; Kelsen, D.P.; Ajani, J.A. PD-L1 expression and overall survival in Asian and Western patients with gastric cancer. Future Oncol., 2022, 18(21), 2623-2634.
[http://dx.doi.org/10.2217/fon-2022-0103] [PMID: 35616013]
[15]
Lian, J.; Zhang, G.; Zhang, Y.; Liu, H.; Zhang, J.; Nan, P.; Tian, W. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. Dig. Liver Dis., 2022, 54(10), 1419-1427.
[http://dx.doi.org/10.1016/j.dld.2022.01.128] [PMID: 35123909]
[16]
Ngoc Dung, T.; Mai Hanh, N.; Thai Tra, D.; Dinh Tien, T.; Thuy Linh, N.; Khac Tuyen, N.; Van Thinh, P.; Nhu Binh, D.; Manh Hung, N.; Thanh Chung, D. The relationship between PD-L1 expression and clinicopathological characteristics and prognosis of Vietnamese gastric cancer patients. Biomed. Res. Ther., 2022, 9(7), 5130-5139.
[http://dx.doi.org/10.15419/bmrat.v9i7.748]
[17]
Dislich, B.; Mertz, K.D.; Gloor, B.; Langer, R. Interspatial distribution of tumor and immune cells in correlation with PD-L1 in molecular subtypes of gastric cancers. Cancers, 2022, 14(7), 1736.
[http://dx.doi.org/10.3390/cancers14071736] [PMID: 35406506]
[18]
Chen, X.; Zhang, H.; Wang, M.; Liu, H.; Hu, Y.; Lin, T.; Chen, H.; Zhao, M.; Chen, T.; Li, G.; Yu, J.; Zhao, L. Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients. Front. Immunol., 2022, 13, 783695.
[http://dx.doi.org/10.3389/fimmu.2022.783695] [PMID: 35401534]
[19]
Che, H.; Xiong, Q.; Ma, J.; Chen, S.; Wu, H.; Xu, H.; Hou, B. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors. BMC Cancer, 2022, 22(1), 904.
[http://dx.doi.org/10.1186/s12885-022-10004-9] [PMID: 35986342]
[20]
Busuioc, C.I.; Birla, R.D.; Mitrea, M.; Ardeleanu, C.; Panaitescu, E.; Enache, S.; Iosif, C. PD-L1 expression in esophageal and gastroesophageal junction carcinoma, correlation with the immune infiltrate - Preliminary study. Chirurgia, 2022, 117(2), 204-210.
[http://dx.doi.org/10.21614/chirurgia.2738] [PMID: 35535782]
[21]
Attia, S.; Abd El Hafez, A.; Abdel-Aziz, A.; Elmetwaly, S.; Mokhtar, N. Prognostic Value of PD-L1 immunohistochemical marker in gastric carcinoma and its correlation with HER2 status. Asian Pac. J. Cancer Prev., 2022, 23(4), 1433-1444.
[http://dx.doi.org/10.31557/APJCP.2022.23.4.1433] [PMID: 35485706]
[22]
Amirmoezi, F.; Geramizadeh, B. Molecular classification of gastric cancer with emphasis on PDL-1 expression: The first report from Iran. Clin. Pathol., 2022, 15, 2632010X2210963.
[http://dx.doi.org/10.1177/2632010X221096378] [PMID: 35651850]
[23]
Zhang, C.; Zhao, S.; Wang, X. Co-expression of CMTM6 and PD-L1: A novel prognostic indicator of gastric cancer. Cancer Cell Int., 2021, 21(1), 78.
[http://dx.doi.org/10.1186/s12935-020-01734-6] [PMID: 33509216]
[24]
Yamashita, S.; Abe, H.; Kunita, A.; Yamashita, H.; Seto, Y.; Ushiku, T. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. Histopathology, 2021, 78(3), 381-391.
[http://dx.doi.org/10.1111/his.14230] [PMID: 32767778]
[25]
Ubukata, Y.; Ogata, K.; Sohda, M.; Yokobori, T.; Shimoda, Y.; Handa, T.; Nakazawa, N.; Kimura, A.; Kogure, N.; Sano, A.; Sakai, M.; Ogawa, H.; Kuwano, H.; Shirabe, K.; Oyama, T.; Saeki, H. Role of PD-L1 expression during the progression of submucosal gastric cancer. Oncology, 2021, 99(1), 15-22.
[http://dx.doi.org/10.1159/000509033] [PMID: 33113541]
[26]
Shi, L.; Wu, Z.; Song, H.; Xu, W.; Xu, Y.; Yang, L.; Song, J.; Guan, W. Intralymph node expressions of A2AR and PD-L1 were associated with metastasis and a poor prognosis in gastric cancer. Indian J. Surg., 2021, 83(2), 505-512.
[http://dx.doi.org/10.1007/s12262-020-02396-4]
[27]
Shekarriz, R.; Hedayatizadeh-Omran, A.; Amjadi, O.; Alizadeh-Navaei, R.; Godazandeh, G. Serum level of programmed death-ligand 1 in patients with gastric cancer in mazandaran province as a high-risk region in Iran. Clin. Cancer Investig. J., 2021, 10(1), 5-10.
[http://dx.doi.org/10.4103/ccij.ccij_128_20]
[28]
Saurabh, A.; Raphael, V.; Dey, B.; Harris, C.; Jagtap, V.; Das, U. Expression of PDL1 and Her2neu in gastric and gastroesophageal junction adenocarcinoma. Indian J. Surg. Oncol., 2021, 12(S1), 144-151.
[http://dx.doi.org/10.1007/s13193-020-01245-w] [PMID: 33994740]
[29]
Pereira, M.A.; Ramos, M.; Dias, A.R.; Ribeiro, R.; Cardili, L.; Zilberstein, B.; Cecconello, I.; Ribeiro, U., Jr; de Mello, E.S.; de Castria, T.B. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Virchows Archiv : Int. J. Pathol., 2021, 478(6), 1039-1048.
[http://dx.doi.org/10.1007/s00428-020-02956-9] [PMID: 33098489]
[30]
Mimura, K.; Kua, L.F.; Xiao, J.F.; Asuncion, B.R.; Nakayama, Y.; Syn, N.; Fazreen, Z.; Soong, R.; Kono, K.; Yong, W.P. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models. Gastric Cancer, 2021, 24(3), 611-623.
[http://dx.doi.org/10.1007/s10120-020-01151-8] [PMID: 33611641]
[31]
Lv, H.; Zhang, J.; Sun, K.; Nie, C.; Chen, B.; Wang, J.; Xu, W.; Wang, S.; Liu, Y.; Chen, X. Expression of human epidermal growth factor receptor-2 status and programmed cell death protein-1 ligand is associated with prognosis in gastric cancer. Front. Oncol., 2021, 10, 580045.
[http://dx.doi.org/10.3389/fonc.2020.580045]
[32]
Li, X.; Zhang, L.; Wang, C.; Huang, J.; Zhu, J.; Huang, Y.; Chen, Y.; Jia, J.; Jiang, G. Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics. J. Gastrointest. Oncol., 2021, 12(6), 2719-2727.
[http://dx.doi.org/10.21037/jgo-21-695] [PMID: 35070401]
[33]
Bahsi, S.; Yildiz, I.; Erdamar, S.; Goksel, S.; Tozun, N.; Aytac, E.; Demir, G.; Er, O.; Baca, B.; Karahasanoglu, T.; Hamzaoglu, I.; Ozer, L.; Bozkurt, M.; Uras, C.; Bayoglu, I.V.; Dulgeroglu, O.; Ince, U. Clinicopathological and prognostic significance of msi status and pd-l1 expression in turkish patients with gastric cancer. UHOD Uluslar. Hematol. Onkol. Derg., 2021, 31(4), 246-254.
[34]
Zhou, K.I.; Peterson, B.; Serritella, A.; Thomas, J.; Reizine, N.; Moya, S.; Tan, C.; Wang, Y.; Catenacci, D.V.T. Spatial and temporal heterogeneity of pd-l1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin. Cancer Res., 2020, 26(24), 6453-6463.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-2085] [PMID: 32820017]
[35]
Yun, T.; Wang, S.; Jiang, B.; Wang, C.; Meng, N.; Yuan, X.; Wang, Y. Significance of detection of the HER2 Gene and PD-1/PD-L1 in gastric cancer. J Oncol., 2020, 2020, 8678945.
[http://dx.doi.org/10.1155/2020/8678945] [PMID: 33123197]
[36]
Yamashita, K.; Iwatsuki, M.; Harada, K.; Eto, K.; Hiyoshi, Y.; Ishimoto, T.; Nagai, Y.; Iwagami, S.; Miyamoto, Y.; Yoshida, N.; Komohara, Y.; Ajani, J.A.; Baba, H. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer, 2020, 23(1), 95-104.
[http://dx.doi.org/10.1007/s10120-019-00999-9] [PMID: 31451991]
[37]
Wang, Y.; Wang, S.; Zhu, C.; Cao, H.; Zhang, Z.; Zhao, E. The association between immune characteristic and clinical pathology in Chinese patients with adenocarcinoma of esophagogastric junction. Cancer Manag. Res., 2020, 12, 3259-3269.
[http://dx.doi.org/10.2147/CMAR.S235722] [PMID: 32494190]
[38]
Wang, X.Y.; Hu, Y.J.; Dong, K.; Zhao, C.; Huang, X.Z.; Lian, S.Y.; Sun, Y. Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer. Chinese J. Pathol., 2020, 49(11), 1114-1119.
[http://dx.doi.org/10.3760/cma.j.cn112151-20200323-00245] [PMID: 33152814]
[39]
Wang, J.; Shang, S.; Li, J.; Deng, H.; Ouyang, L.; Xie, H.; Zhu, H.; Li, Y.; Zuo, C. PD-L1 and MiR-34a are prognostic factors for primary gastric diffuse large B-cell lymphoma patients treated with R-CHOP. Cancer Manag. Res., 2020, 12, 4999-5008.
[http://dx.doi.org/10.2147/CMAR.S247874] [PMID: 32612387]
[40]
Sughayer, M.A.; Dabbagh, T.Z.; Battah, A.H. PD-L1 expression is a favorable prognostic marker in gastric carcinoma. Appl. Immunohistochem. Mol. Morphol., 2020, 28(10), 748-754.
[http://dx.doi.org/10.1097/PAI.0000000000000834] [PMID: 32205740]
[41]
Pötzsch, M.; Berg, E.; Hummel, M.; Stein, U.; von Winterfeld, M.; Jöhrens, K.; Rau, B.; Daum, S.; Treese, C. Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression. OncoImmunology, 2020, 9(1), 1824632.
[http://dx.doi.org/10.1080/2162402X.2020.1824632] [PMID: 33101772]
[42]
Liu, X.; Choi, M.G.; Kim, K.; Kim, K.M.; Kim, S.T.; Park, S.H.; Cristescu, R.; Peter, S.; Lee, J. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol. Res. Pract., 2020, 216(4), 152881.
[http://dx.doi.org/10.1016/j.prp.2020.152881] [PMID: 32089413]
[43]
Lian, J.; Nan, P.; Zhang, G.; Zhang, Y. Correlation between expression of PD-L1 and HER-2 in gastric adenocarcinoma and its prognostic significance. Chinese J. Clin. Experimen. Pathol., 2020, 36(6), 636-641.
[44]
Ito, S.; Masuda, T.; Noda, M.; Hu, Q.; Shimizu, D.; Kuroda, Y.; Eguchi, H.; Tobo, T.; Utsunomiya, T.; Mimori, K. Prognostic significance of PD-1, PD-L1 and CD8 gene expression levels in gastric cancer. Oncology, 2020, 98(7), 501-511.
[http://dx.doi.org/10.1159/000506075] [PMID: 32380498]
[45]
Kim, D.H.; Bae, G.E.; Suh, K.S.; Ryuman, D.; Song, K.S.; Kim, J.S.; Lee, S.; Yeo, M.K. Clinical significance of tumor and immune cell PD-L1 expression in gastric adenocarcinoma. In Vivo, 2020, 34(6), 3171-3180.
[http://dx.doi.org/10.21873/invivo.12152] [PMID: 33144421]
[46]
Choi, E.; Chang, M.S.; Byeon, S.; Jin, H.; Jung, K.C.; Kim, H.; Lee, K.L.; Kim, W.; Park, J.H.; Kim, K.H.; Kim, J.S.; Choi, I.S.; Han, D.S.; Ahn, H.S.; Heo, S.C. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Diagn. Pathol., 2020, 15(1), 69.
[http://dx.doi.org/10.1186/s13000-020-00979-z] [PMID: 32498695]
[47]
Yang, M.W.; Fu, X.L.; Jiang, Y.S.; Chen, X.J.; Tao, L.Y.; Yang, J.Y.; Huo, Y.M.; Liu, W.; Zhang, J.F.; Liu, P.F.; Liu, Q.; Hua, R.; Zhang, Z.G.; Sun, Y.W.; Liu, D.J. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J. Gastroenterol., 2019, 25(14), 1684-1696.
[http://dx.doi.org/10.3748/wjg.v25.i14.1684] [PMID: 31011254]
[48]
Won, K.Y.; Kim, G.Y.; Kim, H.K.; Song, M.J.; Choi, S.I.; Bae, G.E.; Lim, S.J. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor. Pathol. Res. Pract., 2019, 215(11), 152639.
[http://dx.doi.org/10.1016/j.prp.2019.152639] [PMID: 31582185]
[49]
Wang, C.; Yu, J.; Fan, Y.; Ma, K.; Ning, J.; Hu, Y.; Niu, W.; Dong, X.; Wu, Y.; Li, E.; Dong, D. The clinical significance of PD-L1/PD-1 expression in gastroenteropancreatic neuroendocrine neoplasia. Ann. Clin. Lab. Sci., 2019, 49(4), 448-456.
[PMID: 31471333]
[50]
Svensson, M.C.; Borg, D.; Zhang, C.; Hedner, C.; Nodin, B.; Uhlén, M.; Mardinoglu, A.; Leandersson, K.; Jirström, K. Expression of PD-L1 and PD-1 in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma: Relationship with mismatch repair status and survival. Front. Oncol., 2019, 9, 136.
[http://dx.doi.org/10.3389/fonc.2019.00136] [PMID: 30931254]
[51]
Sun, Y.; Yu, W.; Guan, W.; cai, L.; Qiao, M.; Zheng, L.; Jiang, R.; Wang, R.; Wang, L. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Manag. Res., 2019, 11, 6397-6410.
[http://dx.doi.org/10.2147/CMAR.S206189] [PMID: 31372044]
[52]
Mu, L.; Yu, W.; Su, H.; Lin, Y.; Sui, W.; Yu, X.; Qin, C. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. Artif. Cells Nanomed. Biotechnol., 2019, 47(1), 1036-1042.
[http://dx.doi.org/10.1080/21691401.2019.1573741] [PMID: 30983436]
[53]
Morihiro, T.; Kuroda, S.; Kanaya, N.; Kakiuchi, Y.; Kubota, T.; Aoyama, K.; Tanaka, T.; Kikuchi, S.; Nagasaka, T.; Nishizaki, M.; Kagawa, S.; Tazawa, H.; Fujiwara, T. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Sci. Rep., 2019, 9(1), 4633.
[http://dx.doi.org/10.1038/s41598-019-41177-2] [PMID: 30874607]
[54]
Knief, J.; Lazar-Karsten, P.; Hummel, R.; Wellner, U.; Thorns, C. PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival. Pathol. Res. Pract., 2019, 215(6), 152402.
[http://dx.doi.org/10.1016/j.prp.2019.03.030] [PMID: 31043352]
[55]
Kim, J.Y.; Kim, W.G.; Kwon, C.H.; Park, D.Y. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact. Gastric Cancer, 2019, 22(6), 1164-1175.
[http://dx.doi.org/10.1007/s10120-019-00974-4] [PMID: 31152268]
[56]
Kim, J.H.; Kim, S.Y.; Shin, E.Y.; Jung, J.H.; Choi, H.J.; Jun, K.H. Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. Oncol. Lett., 2019, 18(3), 2661-2669.
[http://dx.doi.org/10.3892/ol.2019.10594] [PMID: 31452748] [PMID: 31452748]
[57]
Kawazoe, A.; Shitara, K.; Kuboki, Y.; Bando, H.; Kojima, T.; Yoshino, T.; Ohtsu, A.; Ochiai, A.; Togashi, Y.; Nishikawa, H.; Doi, T.; Kuwata, T. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer, 2019, 22(1), 69-76.
[http://dx.doi.org/10.1007/s10120-018-0843-9] [PMID: 29859006]
[58]
Hashimoto, T.; Kurokawa, Y.; Takahashi, T.; Miyazaki, Y.; Tanaka, K.; Makino, T.; Yamasaki, M.; Nakajima, K.; Ikeda, J.; Mori, M.; Doki, Y. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer, 2019, 22(4), 785-792.
[http://dx.doi.org/10.1007/s10120-018-00918-4] [PMID: 30617648]
[59]
Zhang, F.; Qiao, J.; Wang, Y.; Zhao, F.; Zhang, S.; Zhang, R. Expression and clinical significance of PD-1 /PD-L1 in gastric cancer tissues. Zhongguo Zhongliu Shengwu Zhiliao Zazhi, 2018, 25(2), 170-176.
[60]
Zhang, C.; Li, Z.; Xu, L.; Che, X.; Wen, T.; Fan, Y.; Li, C.; Wang, S.; Cheng, Y.; Wang, X.; Qu, X.; Liu, Y. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. BMC Cancer, 2018, 18(1), 462.
[http://dx.doi.org/10.1186/s12885-018-4384-8] [PMID: 29690901]
[61]
Xing, X.; Guo, J.; Ding, G.; Li, B.; Dong, B.; Feng, Q.; Li, S.; Zhang, J.; Ying, X.; Cheng, X.; Guo, T.; Du, H.; Hu, Y.; Zhou, T.; Wang, X.; Li, L.; Li, Q.; Xie, M.; Li, L.; Gao, X.; Shan, F.; Li, Z.; Jia, S.; Wen, X.; Wang, J.; Ji, J. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. OncoImmunology, 2018, 7(3), e1356144.
[http://dx.doi.org/10.1080/2162402X.2017.1356144] [PMID: 29399387]
[62]
Wei, W.; Zhang, D.; Xu, B.; Jiang, J.; Wu, C. Upregulation of programmed death ligand 1 and epidermal growth factor receptor is associated with poor prognosis in gastric cancer. Transl. Cancer Res., 2018, 7(2), 330-340.
[http://dx.doi.org/10.21037/tcr.2018.03.15]
[63]
Sundar, R.; Qamra, A.; Tan, A.L.K.; Zhang, S.; Ng, C.C.Y.; Teh, B.T.; Lee, J.; Kim, K.M.; Tan, P. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer, 2018, 21(6), 1064-1070.
[http://dx.doi.org/10.1007/s10120-018-0851-9] [PMID: 29915957]
[64]
Saito, H.; Kono, Y.; Murakami, Y.; Shishido, Y.; Kuroda, H.; Matsunaga, T.; Fukumoto, Y.; Osaki, T.; Ashida, K.; Fujiwara, Y. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression. Anticancer Res., 2018, 38(1), 107-112.
[http://dx.doi.org/10.21873/anticanres.12197] [PMID: 29277762]
[65]
Pereira, M.A.; Ramos, M.F.K.P.; Faraj, S.F.; Dias, A.R.; Yagi, O.K.; Zilberstein, B.; Cecconello, I.; Alves, V.A.F.; de Mello, E.S.; Ribeiro, U., Jr Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J. Surg. Oncol., 2018, 117(5), 829-839.
[http://dx.doi.org/10.1002/jso.25022] [PMID: 29534305]
[66]
Noh, B.J.; Kim, J.H.; Eom, D.W. Prognostic significance of categorizing gastric carcinoma by PD-L1 expression and tumor infiltrating lymphocytes. Ann. Clin. Lab. Sci., 2018, 48(6), 695-706.
[PMID: 30610038]
[67]
Liu, Y.; Wang, J.F.; Li, X.W.; Bu, P.; Bai, W.; Li, L.M. Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues. Chinese J. Pathol., 2018, 47(8), 597-602.
[http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2018.08.006] [PMID: 30107664]
[68]
Li, Y.; Bao, F.; Xiang, Y.; Dai, Y.; He, J.; Ma, C.; Zhang, Z. Expression of PD1 /PD-L1 in gastric carcinoma and its correlation with clinicopathological characteristics and prognosis. Chinese J. Clin. Experimen. Pathol., 2018, 34(6), 614-618.
[69]
Harada, K.; Dong, X.; Estrella, J.S.; Correa, A.M.; Xu, Y.; Hofstetter, W.L.; Sudo, K.; Onodera, H.; Suzuki, K.; Suzuki, A.; Johnson, R.L.; Wang, Z.; Song, S.; Ajani, J.A. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer, 2018, 21(1), 31-40.
[http://dx.doi.org/10.1007/s10120-017-0760-3] [PMID: 28801853]
[70]
Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chin. J. Cancer, 2017, 36(1), 61.
[http://dx.doi.org/10.1186/s40880-017-0226-3] [PMID: 28754154]
[71]
Wu, Y.; Cao, D.; Qu, L.; Cao, X.; Jia, Z.; Zhao, T.; Wang, Q.; Jiang, J. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget, 2017, 8(38), 64066-64082.
[http://dx.doi.org/10.18632/oncotarget.19318] [PMID: 28969052]
[72]
Thompson, E.D.; Zahurak, M.; Murphy, A.; Cornish, T.; Cuka, N.; Abdelfatah, E.; Yang, S.; Duncan, M.; Ahuja, N.; Taube, J.M.; Anders, R.A.; Kelly, R.J. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut, 2017, 66(5), 794-801.
[http://dx.doi.org/10.1136/gutjnl-2015-310839] [PMID: 26801886]
[73]
Seo, A.N.; Kang, B.W.; Kwon, O.K.; Park, K.B.; Lee, S.S.; Chung, H.Y.; Yu, W.; Bae, H.I.; Jeon, S.W.; Kang, H.; Kim, J.G. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein–Barr virus-associated gastric cancer. Br. J. Cancer, 2017, 117(12), 1753-1760.
[http://dx.doi.org/10.1038/bjc.2017.369] [PMID: 29073638]
[74]
Oki, E.; Okano, S.; Saeki, H.; Umemoto, Y.; Teraishi, K.; Nakaji, Y.; Ando, K.; Zaitsu, Y.; Yamashita, N.; Sugiyama, M.; Nakashima, Y.; Ohgaki, K.; Oda, Y.; Maehara, Y. Protein expression of programmed death 1 Ligand 1 and HER2 in gastric carcinoma. Oncology, 2017, 93(6), 387-394.
[http://dx.doi.org/10.1159/000479231] [PMID: 28910818]
[75]
Kwon, M.J.; Kim, K.C.; Nam, E.S.; Cho, S.J.; Park, H.R.; Min, S.K.; Seo, J.; Choe, J.Y.; Lee, H.K.; Kang, H.S.; Min, K.W. Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget, 2017, 8(47), 82399-82414.
[http://dx.doi.org/10.18632/oncotarget.19390] [PMID: 29137273]
[76]
Kim, K.J.; Yang, H.K.; Kim, W.H.; Kang, G.H. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget, 2017, 8(35), 58887-58902.
[http://dx.doi.org/10.18632/oncotarget.19439] [PMID: 28938605]
[77]
Kawazoe, A.; Kuwata, T.; Kuboki, Y.; Shitara, K.; Nagatsuma, A.K.; Aizawa, M.; Yoshino, T.; Doi, T.; Ohtsu, A.; Ochiai, A. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer, 2017, 20(3), 407-415.
[http://dx.doi.org/10.1007/s10120-016-0631-3] [PMID: 27629881]
[78]
Ju, X.; Shen, R.; Huang, P.; Zhai, J.; Qian, X.; Wang, Q.; Chen, M. Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer. Oncotarget, 2017, 8(59), 99372-99381.
[http://dx.doi.org/10.18632/oncotarget.22079] [PMID: 29245908]
[79]
Hsu, J.T.; Hsu, C.S.; Le, P.H.; Chen, T.C.; Chou, W.C.; Lin, C.Y.; Yeh, T.S. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. J. Surg. Res., 2017, 211, 30-38.
[http://dx.doi.org/10.1016/j.jss.2016.11.058] [PMID: 28501128]
[80]
Fang, W.; Chen, Y.; Sheng, J.; Zhou, T.; Zhang, Y.; Zhan, J.; Liu, L.; Huang, J.; Peng, P.; Zhang, L. Association between PD-L1 expression on tumour-infiltrating lymphocytes and overall survival in patients with gastric cancer. J. Cancer, 2017, 8(9), 1579-1585.
[http://dx.doi.org/10.7150/jca.18729] [PMID: 28775777]
[81]
Ma, C.; Patel, K.; Singhi, A.D.; Ren, B.; Zhu, B.; Shaikh, F.; Sun, W. Programmed death-ligand 1 expression is common in gastric cancer associated with epstein-barr virus or microsatellite instability. Am. J. Surg. Pathol., 2016, 40(11), 1496-1506.
[http://dx.doi.org/10.1097/PAS.0000000000000698] [PMID: 27465786]
[82]
Li, Z.; Lai, Y.; Sun, L.; Zhang, X.; Liu, R.; Feng, G.; Zhou, L.; Jia, L.; Huang, X.; Kang, Q.; Lin, D.; Gao, J.; Shen, L. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum. Pathol., 2016, 55, 182-189.
[http://dx.doi.org/10.1016/j.humpath.2016.05.012] [PMID: 27260946]
[83]
Eto, S.; Yoshikawa, K.; Nishi, M.; Higashijima, J.; Tokunaga, T.; Nakao, T.; Kashihara, H.; Takasu, C.; Iwata, T.; Shimada, M. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer, 2016, 19(2), 466-471.
[http://dx.doi.org/10.1007/s10120-015-0519-7] [PMID: 26210691]
[84]
Dong, M.; Wang, H.; Zhao, X.; Chen, J.; Zhang, Y.; Huang, Y.; Xue, L.; Li, H.; Du, H.; Wu, X.; Shao, C. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in epstein-barr virus–associated gastric carcinoma. Hum. Pathol., 2016, 53, 25-34.
[http://dx.doi.org/10.1016/j.humpath.2016.02.007] [PMID: 26980034]
[85]
Dai, C.; Geng, R.; Wang, C.; Wong, A.; Qing, M.; Hu, J.; Sun, Y.; Lo, A.W.I.; Li, J. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol. Oncol., 2016, 10(10), 1551-1558.
[http://dx.doi.org/10.1016/j.molonc.2016.09.004] [PMID: 27720576]
[86]
Chang, H.; Jung, W.Y.; Kang, Y.; Lee, H.; Kim, A.; Kim, H.K.; Shin, B.K.; Kim, B. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. Oncotarget, 2016, 7(49), 80426-80434.
[http://dx.doi.org/10.18632/oncotarget.12603] [PMID: 27741514]
[87]
Böger, C.; Behrens, H.M.; Mathiak, M.; Krüger, S.; Kalthoff, H.; Röcken, C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget, 2016, 7(17), 24269-24283.
[http://dx.doi.org/10.18632/oncotarget.8169] [PMID: 27009855]
[88]
Zhang, L.; Qiu, M.; Jin, Y.; Ji, J.; Li, B.; Wang, X.; Yan, S.; Xu, R.; Yang, D. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int. J. Clin. Exp. Pathol., 2015, 8(9), 11084-11091.
[PMID: 26617827]
[89]
Qing, Y.; Li, Q.; Ren, T.; Xia, W.; Peng, Y.; Liu, G.; Luo, H.; Yang, Y.; Dai, X.; Zhou, S.F.; Wang, D. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des. Devel. Ther., 2015, 9, 901-909.
[http://dx.doi.org/10.2147/DDDT.S75152] [PMID: 25733810]
[90]
Geng, Y.; Wang, H.; Lu, C.; Li, Q.; Xu, B.; Jiang, J.; Wu, C. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int. J. Clin. Oncol., 2015, 20(2), 273-281.
[http://dx.doi.org/10.1007/s10147-014-0701-7] [PMID: 24804867]
[91]
Lu, C.; Li, Q.; Wang, H.; Geng, Y.; Tian, B.; Xie, J.; Tan, Y.; Wu, C. Expression and clinical significance of costimulatory molecules B7-H1, B7-H4 and forkhead box P3~+ regulatory T cells in gastric carcinoma. Chin. J. Exp. Surg., 2014, 31(3), 492-494.
[92]
Jiang, D.; Xu, Y.; Li, F.; Xu, B.; Zhang, X. The role of B7-H1 in gastric carcinoma: Clinical significance and related mechanism. Med. Oncol., 2014, 31(11), 268.
[http://dx.doi.org/10.1007/s12032-014-0268-1] [PMID: 25311064]
[93]
Hou, J.; Yu, Z.; Xiang, R.; Li, C.; Wang, L.; Chen, S.; Li, Q.; Chen, M.; Wang, L. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp. Mol. Pathol., 2014, 96(3), 284-291.
[http://dx.doi.org/10.1016/j.yexmp.2014.03.005] [PMID: 24657498]
[94]
Liu, S.M.; Meng, Q.; Zhang, Q.X.; Wang, S.D.; Liu, Z.J.; Zhang, X.F. Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma. Zhonghua Zhong Liu Za Zhi, 2008, 30(3), 192-195.
[PMID: 18756934]
[95]
Sun, J.; Xu, K.; Wu, C.; Wang, Y.; Hu, Y.; Zhu, Y.; Chen, Y.; Shi, Q.; Yu, G.; Zhang, X. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens, 2007, 69(1), 19-27.
[http://dx.doi.org/10.1111/j.1399-0039.2006.00701.x] [PMID: 17212704]
[96]
Wu, C.; Zhu, Y.; Jiang, J.; Zhao, J.; Zhang, X.G.; Xu, N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem., 2006, 108(1), 19-24.
[http://dx.doi.org/10.1016/j.acthis.2006.01.003] [PMID: 16530813]
[97]
Wang, L.; Zhang, Q.; Ni, S.; Tan, C.; Cai, X.; Huang, D.; Sheng, W. Programmed death-ligand 1 expression in gastric cancer: Correlation with mismatch repair deficiency and HER2-negative status. Cancer Med., 2018, 7(6), 2612-2620.
[http://dx.doi.org/10.1002/cam4.1502] [PMID: 29673110]
[98]
Lima, Á.; Sousa, H.; Medeiros, R.; Nobre, A.; Machado, M. PD-L1 expression in EBV associated gastric cancer: A systematic review and meta-analysis. Discover Oncology, 2022, 13(1), 19.
[http://dx.doi.org/10.1007/s12672-022-00479-0] [PMID: 35318527]
[99]
Murphy, G.; Pfeiffer, R.; Camargo, M.C.; Rabkin, C.S. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology, 2009, 137(3), 824-833.
[http://dx.doi.org/10.1053/j.gastro.2009.05.001] [PMID: 19445939]
[100]
Li, X.; Zhang, W. Expression of PD-L1 in EBV-associated malignancies. Int. Immunopharmacol., 2021, 95, 107553.
[http://dx.doi.org/10.1016/j.intimp.2021.107553] [PMID: 33765613]
[101]
Angerilli, V.; Parente, P.; Campora, M.; Ugolini, C.; Battista, S.; Cassoni, P.; Gambella, A.; Cavallin, F.; De Lisi, G.; Vanoli, A.; Grillo, F.; Mastracci, L.; Fassan, M. HER2-low in gastro-oesophageal adenocarcinoma: A real-world pathological perspective. J. Clin. Pathol., 2023, 208767.
[http://dx.doi.org/10.1136/jcp-2023-208767] [PMID: 37055161]
[102]
Dai, X.; Bu, X.; Gao, Y.; Guo, J.; Hu, J.; Jiang, C.; Zhang, Z.; Xu, K.; Duan, J.; He, S.; Zhang, J.; Wan, L.; Liu, T.; Zhou, X.; Hung, M.C.; Freeman, G.J.; Wei, W. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol. Cell, 2021, 81(11), 2317-2331.e6.
[http://dx.doi.org/10.1016/j.molcel.2021.03.037] [PMID: 33909988]
[103]
Li, Z.; Zhang, C.; Du, J.X.; Zhao, J.; Shi, M.T.; Jin, M.W.; Liu, H. Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling. Cancer Cell Int., 2020, 20(1), 179.
[http://dx.doi.org/10.1186/s12935-020-01269-w] [PMID: 32477009]
[104]
Szczyrek, M.; Bitkowska, P.; Chunowski, P.; Czuchryta, P.; Krawczyk, P.; Milanowski, J. Diet, microbiome, and cancer immunotherapy-A comprehensive review. Nutrients, 2021, 13(7), 2217.
[http://dx.doi.org/10.3390/nu13072217] [PMID: 34203292]
[105]
Handford, J.; Chen, M.; Rai, R.; Moss, C.L.; Enting, D.; Peat, N.; Karagiannis, S.N.; Van Hemelrijck, M.; Russell, B. Is there a role for exercise when treating patients with cancer with immune checkpoint inhibitors? A scoping review. Cancers, 2022, 14(20), 5039.
[http://dx.doi.org/10.3390/cancers14205039] [PMID: 36291823]
[106]
Zhao, Y.; Jia, Y.; Shi, T.; Wang, W.; Shao, D.; Zheng, X.; Sun, M.; He, K.; Chen, L. Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells. Carcinogenesis, 2019.
[http://dx.doi.org/10.1093/carcin/bgz017] [PMID: 30715244]
[107]
Huang, K.W.; Huang, T.L. Association between programmed death-1 pathway and major depression. World J. Biol. Psychiatry, 2023, 1-7.
[http://dx.doi.org/10.1080/15622975.2023.2209876] [PMID: 37139744]
[108]
Dickinson, S.E.; Khawam, M.; Kirschnerova, V.; Vaishampayan, P.; Centuori, S.M.; Saboda, K.; Calvert, V.S.; Petricoin, E.F., III; Curiel-Lewandrowski, C. Increased PD-L1 expression in human skin acutely and chronically exposed to UV irradiation. Photochem. Photobiol., 2021, 97(4), 778-784.
[http://dx.doi.org/10.1111/php.13406] [PMID: 33615483]
[109]
Zhang, M.; Dong, Y.; Liu, H.; Wang, Y.; Zhao, S.; Xuan, Q.; Wang, Y.; Zhang, Q. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients. Sci. Rep., 2016, 6(1), 37933.
[http://dx.doi.org/10.1038/srep37933] [PMID: 27892511]
[110]
Ren, J.; He, Q.; Yin, H.; Zheng, L.; Li, L.; Wu, X. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: A systematic review and meta-analysis. Clin. Transl. Oncol., 2023, 25(5), 1436-1445.
[http://dx.doi.org/10.1007/s12094-022-03040-1] [PMID: 36528835]

Rights & Permissions Print Cite
Article Metrics
23
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy